Learn more

UROGENESYS INC

Overview
  • Total Patents
    55
About

UROGENESYS INC has a total of 55 patent applications. Its first patent ever was published in 1999. It filed its patents most often in WIPO (World Intellectual Property Organization), Australia and Canada. Its main competitors in its focus markets pharmaceuticals, biotechnology and agriculture are LUDWIG INST CANCER RES, SAHIN UGUR and BIONTECH AG.

Patent filings per year

Chart showing UROGENESYS INCs patent filings per year from 1900 to 2020

Top inventors

# Name Total Patents
#1 Hubert Rene S 46
#2 Raitano Arthur B 30
#3 Afar Daniel E 29
#4 Jakobovits Aya 21
#5 Afar Daniel E H 18
#6 Mitchell Steve Chappell 14
#7 Saffran Douglas C 14
#8 Mitchell Stephen Chappell 13
#9 Leong Kahan 12
#10 Faris Mary 11

Latest patents

Publication Filing date Title
AU7504101A 98p7c3: homeodomain protein highly expressed in various cancers
AU3814401A 83p5g4: a tissue specific protein highly expressed in prostate cancer
WO0159110A2 34p3d7: a tissue specific protein highly expressed in prostate cancer
AU3797301A 84p2a9: a prostate and testis specific protein highly expressed in prostate cancer
WO0131015A2 36p6d5: secreted tumor antigen
WO0131343A2 Diagnosis and therapy of cancer using sgp28-related molecules
AU1345301A Gene upregulated in cancers of the prostate
WO0112811A1 C-type lectin transmembrane antigen expressed in human prostate cancer and uses thereof
AU1097500A Human gene expressed in cancers of prostate, bladder, pancreas and colon, 36p1a6
IL142311D0 Methods and compositions for the diagnosis and therapy of prostate cancer
WO0020589A2 PTANs: TESTIS SPECIFIC PROTEINS EXPRESSED IN PROSTATE CANCER
IL142194D0 Gene expressed in prostate cancer
IL141444D0 Phelix: a testis specific protein expressed in cancer
CA2338982A1 Bpc-1: a secreted brain specific protein expressed and secreted by prostate and bladder cancer cells
IL139988D0 Tumor antigen useful in diagnosis and therapy of prostate and colon cancer
CA2324206A1 Prostapin gene and protein and uses thereof